106 related articles for article (PubMed ID: 22505519)
1. Characterization of SPINK9, a KLK5-specific inhibitor expressed in palmo-plantar epidermis.
Brännström K; Ohman A; von Pawel Rammingen U; Olofsson A; Brattsand M
Biol Chem; 2012 Apr; 393(5):369-77. PubMed ID: 22505519
[TBL] [Abstract][Full Text] [Related]
2. SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor.
Brattsand M; Stefansson K; Hubiche T; Nilsson SK; Egelrud T
J Invest Dermatol; 2009 Jul; 129(7):1656-65. PubMed ID: 19194479
[TBL] [Abstract][Full Text] [Related]
3. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
4. The serine protease inhibitor of Kazal-type 9 (SPINK9) is expressed in lichen simplex chronicus, actinic keratosis and squamous cell carcinoma.
Redelfs L; Fischer J; Weber C; Wu Z; Meyer-Hoffert U
Arch Dermatol Res; 2016 Mar; 308(2):133-7. PubMed ID: 26746658
[TBL] [Abstract][Full Text] [Related]
5. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases.
Meyer-Hoffert U; Wu Z; Kantyka T; Fischer J; Latendorf T; Hansmann B; Bartels J; He Y; Gläser R; Schröder JM
J Biol Chem; 2010 Oct; 285(42):32174-81. PubMed ID: 20667819
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6.
Kantyka T; Fischer J; Wu Z; Declercq W; Reiss K; Schröder JM; Meyer-Hoffert U
Peptides; 2011 Jun; 32(6):1187-92. PubMed ID: 21439340
[TBL] [Abstract][Full Text] [Related]
7. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.
Deraison C; Bonnart C; Lopez F; Besson C; Robinson R; Jayakumar A; Wagberg F; Brattsand M; Hachem JP; Leonardsson G; Hovnanian A
Mol Biol Cell; 2007 Sep; 18(9):3607-19. PubMed ID: 17596512
[TBL] [Abstract][Full Text] [Related]
8. SPINK9 stimulates metalloprotease/EGFR-dependent keratinocyte migration via purinergic receptor activation.
Sperrhacke M; Fischer J; Wu Z; Klünder S; Sedlacek R; Schroeder JM; Meyer-Hoffert U; Reiss K
J Invest Dermatol; 2014 Jun; 134(6):1645-1654. PubMed ID: 24441102
[TBL] [Abstract][Full Text] [Related]
9. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
10. Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
de Veer SJ; Swedberg JE; Brattsand M; Clements JA; Harris JM
Biol Chem; 2016 Dec; 397(12):1237-1249. PubMed ID: 26894578
[TBL] [Abstract][Full Text] [Related]
11. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade.
Eissa A; Amodeo V; Smith CR; Diamandis EP
J Biol Chem; 2011 Jan; 286(1):687-706. PubMed ID: 20940292
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury.
Fischer J; Wu Z; Kantyka T; Sperrhacke M; Dimitrieva O; Koblyakova Y; Ahrens K; Graumann N; Baurecht H; Reiss K; Schröder JM; Proksch E; Meyer-Hoffert U
J Invest Dermatol; 2014 May; 134(5):1305-1312. PubMed ID: 24352040
[TBL] [Abstract][Full Text] [Related]
13. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.
Borgoño CA; Michael IP; Komatsu N; Jayakumar A; Kapadia R; Clayman GL; Sotiropoulou G; Diamandis EP
J Biol Chem; 2007 Feb; 282(6):3640-52. PubMed ID: 17158887
[TBL] [Abstract][Full Text] [Related]
14. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
Fortugno P; Furio L; Teson M; Berretti M; El Hachem M; Zambruno G; Hovnanian A; D'Alessio M
Hum Mol Genet; 2012 Oct; 21(19):4187-200. PubMed ID: 22730493
[TBL] [Abstract][Full Text] [Related]
15. Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum.
Stefansson K; Brattsand M; Ny A; Glas B; Egelrud T
Biol Chem; 2006 Jun; 387(6):761-8. PubMed ID: 16800737
[TBL] [Abstract][Full Text] [Related]
16. The full-length cDNA of anticoagulant protein infestin revealed a novel releasable Kazal domain, a neutrophil elastase inhibitor lacking anticoagulant activity.
Lovato DV; Nicolau de Campos IT; Amino R; Tanaka AS
Biochimie; 2006 Jun; 88(6):673-81. PubMed ID: 16469426
[TBL] [Abstract][Full Text] [Related]
17. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes.
Nin M; Katoh N; Kokura S; Handa O; Yoshikawa T; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):17-24. PubMed ID: 19118981
[TBL] [Abstract][Full Text] [Related]
18. KLK14 interactions with HAI-1 and HAI-2 serine protease inhibitors: A molecular dynamics and relative free-energy calculations study.
Solís-Calero C; Carvalho HF
Cell Biol Int; 2017 Nov; 41(11):1246-1264. PubMed ID: 28817220
[TBL] [Abstract][Full Text] [Related]
19. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
[TBL] [Abstract][Full Text] [Related]
20. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.
Mukai S; Fukushima T; Naka D; Tanaka H; Osada Y; Kataoka H
FEBS J; 2008 Mar; 275(5):1003-17. PubMed ID: 18221492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
